Steminent Biotherapeutics Inc.

Steminent Biotherapeutics Inc. is a biopharmaceutical company operating in Taiwan and the United States. Its cell therapy product, Stemchymal, targets neurodegenerative diseases such as spinocerebellar ataxia and Huntington's disease, tissue regeneration including osteoarthritis, and acute syndromes such as acute respiratory distress syndrome, liver failure, and ischemic stroke. The company was founded in 2009 and is based in Taipei, Taiwan.